Skip to main content

Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina

Buy Article:

$34.78 + tax (Refund Policy)

SETTING: An Argentinean reference hospital specialising in infectious diseases.

OBJECTIVE: To assess the outcomes of all human immunodeficiency virus (HIV) negative multidrug-resistant tuberculosis (MDR-TB) patients referred to or diagnosed at Hospital Muñiz.

DESIGN: Clinical study for the period 1996–1999, with follow-up until June 2002.

RESULTS: One hundred and forty-one adult patients (52.5% female) with resistance to two to seven drugs were studied. Fifty patients (35.5%) had not been treated previously. The most frequently used second-line drugs were 5-F-quinolones, cycloserine and ethionamide in susceptibility based individually tailored three- to five-drug regimens. Hospital admission was associated with treatment success. Forty-five episodes of severe toxicity occurred. Treatment was successful in 51.8% of cases, but follow-up of 73 patients yielded 11.9% relapse. The mortality rate was 19.1% and default was 19.9%. Logistic regression analysis was statistically significant for treatment success in relation to patient admission, residence and resistance pattern.

CONCLUSION: The burden of MDR-TB in this setting—prolonged infection, treatment cost and difficulties, low rates of cure and treatment adherence and high rates of fatality and relapse—can be improved by strengthening TB control programme activities and fighting against poverty and HIV/AIDS.

Keywords: HIV-negative patients; multidrug-resistant tuberculosis; treatment; treatment outcome

Document Type: Regular Paper

Affiliations: 1: Department of Pneumonology, Hospital Muñiz, Buenos Aires, Argentina 2: Department of Pharmacology, Centro de Educación Médica e Investigación Clínica (CEMIC), Buenos Aires, Argentina

Publication date: 01 June 2004

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content